explore -WSS

explore

author：leisure time 2025-10-01 02:16:15 - browse：18361

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Coloradans with cystic fibrosis could lose access to Trikafta

Wikipedia

WSS

Gene therapy’s promise and the high cost of hope

A new House health package & hospitals’ new site

Advances in CAR

Medicare must police algorithms in Medicare Advantage, Dems say

How to convince healthy people to buy insurance

Bill would allow buprenorphine prescription for addiction via telehealth

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How one medical school became remarkably diverse

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Jerome Adams on the need for new antivirals for Covid

Inari Medical to buy amputation prevention company LimFlow

Hepatitis C has a cure — but many Americans still lack access to it

Infant mortality in U.S. rose last year for first time in decades: CDC

Tori Bowie and the unacceptable rates of Black maternal death

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Trump surgeon general acknowledges mistakes during Covid

leisure time

Humans aren't the only ones with an imagination. Rats have it too

Bill would allow buprenorphine prescription for addiction via telehealth

The health care issue Democrats can’t solve: hospital reform

Ethical issues complicate the benefits of medical crowdfunding

'Make People Better': The CRISPR babies story you probably don't know

Crinetics acromegaly drug succeeds in late

explore

entertainment

Wikipedia

focus